Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration

Launched by MEDICAL UNIVERSITY OF VIENNA · Nov 24, 2020

Keywords

ClinConnect Summary

**Summary of the Clinical Trial on Nimodipine Administration in Patients with Aneurysmal Subarachnoid Hemorrhage**

This clinical trial is studying how well a medication called nimodipine can enter the brain when given in different ways—by mouth, through an IV, or directly into an artery—in patients with a serious condition known as aneurysmal subarachnoid hemorrhage (a type of brain bleed). The goal is to understand how nimodipine affects brain health, particularly in preventing complications like delayed cerebral ischemia, which can happen after the initial bleed. Researchers want to measure nimodipine levels in the blood and brain, as well as how it influences brain metabolism and oxygen levels.

To participate in this trial, patients must be adults over 18 years old who have experienced an aneurysmal subarachnoid hemorrhage and are currently sedated and on a ventilator due to the severity of their condition. They must also be receiving brain monitoring as part of their standard care. Participants will be closely monitored, and the trial aims to gather important information that could help improve treatment for patients with similar brain conditions in the future. If you or a loved one meets these criteria, this study could provide valuable insights into the effects of nimodipine on brain health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patient age \> 18 years
• • aneurysmal subarachnoid hemorrhage
• • sedated and mechanically ventilated
• • application of brain microdialysis as standard care (due to the severity of subarachnoid haemorrhage or secondary deterioration)
• • oral, intra-venous or intra-arterial administration of nimodipine due to clinical indication
• Exclusion Criteria:
• • contraindication for nimodipine
• • no need of intensive care and bedside cerebral microdialysis as standard care
• • any disease considered relevant for proper performance of the study or risks to the patient, at the discretion of the investigator